T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells, Tregs, and TILs. It plays a role in NK cell and T cell exhaustion, particularly in cancer. TIGIT’s primary ligand, CD155, is a key target for immunotherapy, with studies showing that cancer treatment responses to anti-PD-1 therapy are linked to CD155 rather than TIGIT.
However, anti-TIGIT therapies have failed in numerous clinical trials this past year, such as Roche’s tiragolumab, Merck’s vibostolimab, Gilead Sciences’ domvanalimab, and Bristol Myers Squibb’s AGEN1777. Despite the disappointing results, iTeos Therapeutics and GSK have presented positive results for their anti-TIGIT drug, garnering some much needed excitement at the ESMO (European Society for Medical Oncology) conference this September.
Currently in development by iTeos Therapeutics and GSK, Belrestotug (EOS-448) is an IgG4 mAb aimed to treat lung cancer. It is the only TIGIT program that has gone through the FDA’s Project Optimus, which aims to reform the dose optimization and dose selection paradigm in oncology drug development. Currently, it is in Phase 3 trials.
This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year
The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.
Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-
The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which
ScientistとScience Exchangeとのご利用可能です。
